Abstract. The clinical symptoms of rheumatoid arthritis (RA) present with circadian variation, with joint stiffness and pain more prominent in the early morning. The mammalian clock genes, which include circadian locomotor output cycles kaput, brain and muscle Arnt-like protein 1, period and cryptochrome, regulate circadian rhythms. In order to identify the association between genetic polymorphisms in the circadian clock gene period 2 (PER2) and RA, the present study genotyped three PER2 single nucleotide polymorphisms (SNPs), rs934945, rs6754875, and rs2304674, using genetic information from 256 RA patients and 499 control subjects. Primary cultured rheumatoid synovial cells were stimulated with 10 µM lipopolysaccharide (LPS). Total protein was then extracted from the synovial cells following 12 and 24 h, and PER2 protein expression was assayed by immunoblotting. The rs2304674 SNP demonstrated a significant association with susceptibility to RA following Bonferroni correction. However, statistical analysis indicated that the SNPs were not associated with any clinical features of patients with RA. Immunoblotting analysis demonstrated that PER2 protein expression was decreased by LPS-induced inflammation in RA synovial cells; however, this was not observed in normal synovial cells. The results suggest that the PER2 gene may be a risk factor for RA, and expression of the PER2 protein may be affected by inflammation. Therefore, PER2 may contribute to the pathogenesis of RA.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammatory cell infiltration, progressive destruction of cartilage and bone, and synovial cell hyperplasia and hypertrophy (1) . RA patients typically experience joint pain, stiffness and functional disability in the early morning h (2) . Patients with chronic inflammatory diseases exhibit disrupted circadian rhythms (3, 4) .
Several studies have reported a bi-directional interaction between inflammation and the circadian clock (5) (6) (7) . Immune system performance is significantly affected by disruption of the circadian clock (6) , and the cellular expression of core clock genes directly alters inflammation (7) . This phenomenon may negatively impact the pathogenesis of RA. In addition, disturbances in the circadian clock have serious effects on a number of diseases, including immune-mediated disorders of the brain (7), infections (8, 9) , cardiovascular disease and sleep disorders (10) . The molecular mechanisms underlying circadian rhythm regulation involve an interplay between feedback and feed-forward transcriptional loops including clock genes, such as circadian locomotor output cycles kaput (CLOCK), brain and muscle ARNT like-1 (BMAL1), rar-related orphan receptor α, deleted in esophageal cancer-1 and -2, cryptochrome (CRY)-1 and -2, nuclear receptor subfamily 1 group D member 1 and period (PER)-1, -2, and -3 (11) (12) (13) (14) , which alter the expression of a number of clock-controlled genes (15) .
Amongst the clock genes, period 2 (PER2) is located on the long arm of chromosome 2 at position 37.3, and encompasses
PER2 is downregulated by the LPS-induced inflammatory response in synoviocytes in rheumatoid arthritis and is implicated in disease susceptibility
25 exons encoding PER2 proteins, which are key molecular components in controlling mammalian circadian rhythms at the level of gene expression, physiology and pathology (16) . PER2 inhibits transcriptional activation of CLOCK/BMAL1 in vitro (17, 18) by binding to enhancer-box motifs in their respective promoters (19) . PER proteins are phosphorylated by several isoforms of casein kinase 1 in a complex manner, which regulates their degradation and nuclear trafficking (20) . In addition, PER1 and PER2 form stable complexes with the casein kinases and either of the CRY proteins (17, 21) . PER proteins are the rate-limiting component for this step, and are necessary for nuclear import of the complex; they serve as shuttles for nuclear CRY proteins (22) . Nuclear CRY and PER proteins inhibit the activity of the heterodimeric BMAL1-CLOCK complex (BCC), potentially via different mechanisms (17) , thereby terminating four negative feedback loops and regulating the expression of CRY and PER genes. PER2 serves a role in the positive regulation of aryl hydrocarbon receptor nuclear translocator like (ARNTL, also known as BMAL1) expression (23) . In humans, a single mutation in PER2 causes familial advanced sleep phase syndrome (24) , and its loss causes arhythmicity in mice (25, 26) . The behavioral phenotypes of Per1-null mutant mice are similar to those of Per2 mutants; however, comparison of the molecular consequences of these mutations revealed significant differences between the two. Disruption of Per2 expression was reported to result in reduced transcription levels of further clock genes, whereas Per1 appeared to function predominantly at the posttranscriptional level (26) . Previous studies have suggested that the circadian rhythm is associated with cortisol levels; cortisol levels are highest in the early morning immediately after awakening, whereas they are low at around midnight (27, 28) . In addition, the circadian clock gene PER2, which is generated in the suprachiasmatic nucleus of the hypothalamus (29) , is associated with the hypothalamic-pituitary-adrenal axis, stress (30) , and neuroendocrine-immunologic pathways, which are relevant to rheumatic diseases (30, 31) . Based on these observations, the present study aimed to investigate the association between polymorphisms in the PER2 gene in Korean RA patients, and to determine the expression levels of PER2 in synovial RA cells during lipopolysaccharide (LPS)-induced inflammation.
Materials and methods

Subjects.
A case-control study was conducted to determine the genetic association between PER2 single nucleotide polymorphisms (SNPs) and RA. A total of 256 unrelated patients with RA (age, 50.47±12.85 years; male/female, 47/209) were enrolled between January and February 2008 from the rheumatic center of Kyung Hee University Hospital (Seoul, Korea). Each patient was diagnosed by a rheumatologist according to ACR 1987 Rheumatoid Arthritis diagnostic criteria (32) . A total of 499 control subjects (age, 46.05±12.67; male/female, 215/284) that participated in a general health checkup program of Kyung Hee University Hospital were recruited. Patients with diabetes (fasting blood sugar >120 mg), hypertension (systolic blood pressure >140 mm Hg and/or diastolic blood pressure >90 mm Hg), dyslipidemia (total cholesterol >200 mg/dl and triglyceride levels >150 mg/dl), obesity (body mass index (BMI) >30 kg/m 2 ), smoking or previous history of smoking 5 years ago, postmenopausal women, evidence of cardio vascular disease or family history of coronary heart disease were excluded from the present study. This study was performed in accordance with the guidelines set forth by the Declaration of Helsinki, and written informed consent was obtained from all subjects. This study was approved by the ethics review committee of the Medical Research Institute, School of Medicine, Kyung Hee University. Demographic data were obtained from patient medical records or through interviews at the time of enrollment. Disease activity was determined on the basis of the following biochemical parameters: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and titer of rheumatoid factor (RF). X-rays of the hands and feet were obtained from all patients and radiographic findings were used to classify patients with bone erosion.
Human SNP genotyping. PER2 SNPs were identified using National Center for Biotechnology Information websites (www. ensembl.org; www.ncbi.nlm.nih.gov/SNP; and www.hapmap. org). A total of 3 PER2 SNPs were selected for analysis, as previously described (33, 34) . The three selected SNPs consisted of one nonsynonymous SNP (rs934945) and two intronic SNPs (rs2304674 and rs6754875). Blood samples were drawn from all subjects following overnight fasting. DNA was isolated from whole blood samples of each subject using the GenEx™ Blood kit (cat. no. 220-301; GeneAll Biotechnology, Co., Ltd., Seoul, Korea), according to the manufacturer's instructions. PER2 SNPs were genotyped according to a previously described method (35) . Genomic DNA was amplified by polymerase chain reaction (PCR) using primers for each SNP. Oligonucleotide primers of PER2 were the following: rs934945, sense 5'-GACTTCTGGGAGCACTG GG-3', antisense 3'-CGTGTTAGCCAGGAAGGTCT-5'; rs6754875, sense 5'-TTGTCATGGCAGCTGTCTCT-3', antisense 3'-TAGGGGAGAAAACCAGGAGA-5'; and rs2304674, sense 5'-TTGTCATGGCAGCTGTCTCT-3' and antisense 3'-TAGGGGAGAAAACCAGGAGA-5'. The PCR products were sequenced using an ABI PRISM 3730xl DNA analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The sequence data were analyzed using SeqManII software version 6.1 (DNASTAR, Inc., Madison, WI, USA).
Cell culture and treatment. Human articular cartilage was sliced and washed in serum-free Dulbecco's modified Eagle's medium (DMEM; WELGENE, Inc., Gyeongsan, Korea) containing D-glucose, L-glutamine, sodium pyruvate and sodium bicarbonate, prior to digestion with 0.1% collagenase (Invitrogen; Thermo Fisher Scientific, Inc.) for 3 h at 37˚C. Undigested fragments were removed by filtration of the solution through a nylon mesh (70 µm mesh size; BD Biosciences, Franklin Lakes, NJ, USA). Isolated cells were washed three times with PBS (pH 7.4), centrifuged at 211 x g for 10 min at room temperature and then resuspended in serum-free DMEM (WELGENE, Inc.). Subsequently, cells were incubated in DMEM supplemented with 20% fetal bovine serum (FBS; WELGENE, Inc.) and containing D-glucose, L-glutamine, sodium pyruvate, sodium bicarbonate, 100 U/ml penicillin and 100 µg/ml streptomycin (WELGENE, Inc.) for 4 days at 37˚C in a 5% CO 2 atmosphere, until they reached 70-80% confluency. The morphological features and the expression levels of type II collagen and aggrecan were consistent with a chondrocytic phenotype. The cells were passaged upon reaching confluence by gentle trypsinization; cells were used for experiments between passage 4 and 8. Following stimulation with LPS (10 µM; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), the cells were collected at 12 and 24 h.
Western blot analysis. RA and normal synovial cells were cultured in 10-cm culture dishes to ~80% confluence (1x10 6 cells/well) and were serum-starved in DMEM without FBS for 24 h. The cells were subsequently incubated for a further 12 or 24 h in the presence of LPS. Cells were lysed in NP40 buffer (ELPIS-Biotech, Inc., Daejeon, Korea) containing 1 mM PMSF protease inhibitor. Protein concentration was measured using a colorimetric Bio-Rad Protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Equal amounts of protein (50 µg) were separated by 12% SDS-PAGE, and transferred onto polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Following blocking with 5% skimmed milk, membranes were probed with anti-PER2 (dilution, 1:1,000; cat. no. ab64460; Abcam, Cambridge, UK) or anti-β-actin (dilution, 1:1,000; cat. no. sc-81178; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) antibodies overnight at 4˚C. Subsequently, the membrane was washed in TBS containing 0.1% Tween-20, and incubated with the following horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature: Anti-mouse immunoglobulin (Ig) G (dilution 1:10,000; cat. no. A9044; Sigma-Aldrich; Merck KGaA) or anti-rabbit IgG (dilution, 1:2,000; cat. no. sc-2004; Santa Cruz Biotechnology, Inc.). Protein bands were visualized using the WesternBright™ enhanced chemiluminescence kit (Advansta, Inc., Menlo Park, CA, USA). The images were captured using the ChemiDoc™ XRS+imaging system (Bio-Rad Laboratories, Inc.). Protein bands were quantified using ImageJ image analysis software version, 1.40 (National Institutes of Health, Bethesda, MD, USA). Experiments were performed in triplicate.
Statistical analysis. The Hardy-Weinberg equilibrium (HWE) was assessed using SNPStats (https://www.snpstats. net/snpstats/start.htm?q=snpstats/start.htm). SNPStats and SNPAnalyzer Pro version 1.0 (Istech Corp., Goyang, Korea) were also used to evaluate the odds ratios (ORs), 95% confidence intervals (CIs), and P-values. Multiple logistic regression analysis, adjusted for age and gender as covariables, was performed. In the logistic regression analysis for each SNP, models were used that assumed the following: Co-dominant inheritance, in which the relative hazard differs between subjects with 1 minor allele and those with 2 minor alleles; dominant inheritance, in which subjects with 1 or 2 minor alleles have the same relative hazard; or recessive inheritance, in which subjects with 2 minor alleles are at increased risk for the disease. Bonferroni correction (P c ) was applied by multiplying the P-values by the number of SNPs (n=3). The χ 2 test was used to compare allele frequencies between groups. To avoid coincidental findings due to multiple testing, a Bonferroni correction was applied by decreasing the significance level to P=0.01 (P=0.05/5) for each of the three SNPs. Western blotting results are presented as the mean ± standard deviation and/or standard error of the mean. Differences between groups were compared using the Student's t-test. Statistical analysis of western blotting results was performed using IBM SPSS software version, 19.0 (IBM SPSS, Armonk, NY USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Subject characteristics.
The clinical and demographic characteristics of the RA patients and control subjects are presented in Table I . The mean age (± standard deviation) of the RA patients and the control subjects was 50.47±12.85 and 46.05±12.67 years, respectively. There were 47 male and 209 female (n=256) RA patients and 215 male and 284 female (n=499) control subjects. RA patients were classified into clinical subgroups according to ESR level (≥30 or <30 mm/h), CRP level (≥0.5 or <0.5 mg/dl), and the presence or absence of RF and bone erosion. A total of 160 RA patients (62.5%) presented with ESR levels of ≥30 mm/h and 96 (37.5%) with an ESR level of <30 mm/h. A total of 182 patients with RA (71.09%) exhibited CRP levels of ≥0.5 mg/dl and 74 (28.91%) patients displayed a CRP level of <0.5 mg/dl. There were Table III) . The CC genotype was associated with a decreased risk of RA (Table II) . In the dominant model, genotypes containing the C allele (CC/TC) and not containing the C allele (TT) made up 44.7 and 55.3% in the control group, and 33.9 and 66.1% in the RA group, respectively (Table III) . The rs2304674 allele was significantly associated with RA (OR=2.02, 95% CI: 1.55-2.63, P<0.001, P c <0.001; Table II ). The rs2304674 T allele frequency was higher in the RA (80.2%) when compared with the control group (66.8%; Table III ). The frequency of the rs6754875 allele was loosely associated with the development of RA. The C allele of rs6754875 was less prevalent in the RA group (24.8%) than in the control group (30.1%; Table III); however, the difference was not significant following Bonferroni correction (Table II) . The association between the 3 SNPs and the clinical characteristics of the RA patients was then assessed and included ESR, CRP, RF and bone erosion parameters. However, no significant differences were observed in these factors among the subgroups (data not shown).
Expression of PER2 in RA synovial cells during LPS-induced inflammatory response.
The protein expression levels of PER2 in normal and RA synovial cells were examined by western blot analysis. The results demonstrated that the expression levels of PER2 were not significantly altered in RA synovial cells when compared with control cells under normal physiological conditions (Fig. 1) . By contrast, the expression of PER2 was significantly decreased in RA synoviocytes following LPS stimulation for 24 h, whereas normal synovial cells were unaffected (Fig. 1) . The protein levels of PER2 decreased in a time-dependent manner in RA synovial cells (Fig. 2) .
Discussion
The purpose of the present study was to evaluate the association between genetic polymorphisms in PER2 and susceptibility to RA, and to compare the protein expression levels of PER2 in normal and RA synoviocytes. An association between specific SNPs of the PER2 gene and RA was observed; the rs2304674 SNP of the PER2 gene was associated with RA, with the CC genotype associated with a decreased risk of RA. In addition, immunoblotting was performed to assess PER2 expression in RA synovial cells compared with normal cells. The results revealed that PER2 expression decreased following LPS treatment for 12 and 24 h in RA cells, whereas no significant effect of LPS treatment on PER2 expression in control cells was observed.
Previous studies have demonstrated that LPS modifies the biological clock (5,6) via alterations in the expression of several circadian clock genes, including Per2 (36) . It has been suggested that LPS impacts on the timing of the circadian rhythm by altering the levels of proinflammatory cytokines in the brain (36) , and thus affects rheumatic diseases (37) . Immune signaling molecules affect circadian rhythms; however, the circadian system in turn regulates the immune system. A number of immune markers have been implicated in circadian regulation, including interleukin (IL)-2, IL-10, granulocyte-macrophage colony stimulating factor, C-C motif chemokine receptor 2, IL-6, IL-1β, tumor necrosis factor (TNF)-α, monocyte chemotacticprotein-1, interferon (IFN)-γ  and IFN receptors (38,39) . In addition, genetic manipulations of circadian timing modulate innate immunity. A previous study demonstrated that the daily rhythm of IFN-γ mRNA and protein expression was absent in Per2-mutant mice (40) . Furthermore, these mice were deficient in their ability to produce IL-10 and IFN-γ in response to LPS (41) . Notably, macrophages display endogenous rhythms in clock gene expression (39, 42) , phagocytosis (43) and LPS sensitivity (44) .
In a previous study, Hashiramoto et al (43) investigated the association between mammalian clock genes and arthritis using knockout animals and collagen-induced arthritis animal models. The authors examined whether the daily expression of clock genes in the synovial cells of foot joints was altered by the induction of arthritis using a mixture of anti-type II collagen monoclonal antibodies and LPS. In naive C57/BL6 mouse joints, daily expression of nuclear PER2 was lower during the daylight (8:00 a.m.) and higher at night (8:00 p.m.), whereas in arthritic joints, PER2 was expressed even during daylight (8:00 a.m.). Induction of arthritis resulted in a 6 h retrograde shift in Per1/2 mRNA expression. The authors suggested that normal circadian gene expression profiles are significantly disturbed in arthritic conditions (43) . In the study, an influence of arthritis on clock gene expression was reported in wild-type mice that were administered with an anti-collagen antibody and LPS, following the assessment of PER2 protein levels in the synovium (42) . They found that PER2 is usually expressed at night; however, in the arthritis model PER2 was highly expressed in the morning. In addition, the phase of Per1 and Per2 mRNA expression in spleen lymphocytes was shifted back ~6 h, and overall Bmal1, Per1, and Per2 mRNA expression levels were reduced. Furthermore, the authors observed that TNF-α inhibited the expression of PER2 in RA fibroblast-like synoviocytes, and it was suggested that the onset of arthritis may impact on the expression of clock genes in vivo (44) . Decreased expression of PER2 by TNF-α may additionally contribute to the resistance of synovial cells to apoptosis, and may contribute to tumor-like growth of the synovium. In agreement with previous studies, the expression of PER2 observed in the present study was similar between control and RA synoviocytes under normal conditions; however, expression was decreased in RA synoviocytes following induction of the inflammatory response. The present study was the first to investigate the potential effect of PER2 SNPs and PER2 expression in RA. The results indicate that PER2 polymorphisms may contribute to increased RA susceptibility via alterations in PER2 protein expression. PER2 may be one of several genes that serve a role in polygenic susceptibility to RA. Due to the relatively small number of subjects in the current study, these findings must be validated by future studies using larger sample sizes. In addition, a substantial difference was present in the sex ratio of the study population. Sex and age were adjusted for during all statistical analyses; however, this inconsistency is a limitation of the current study and further validation is required. Future investigations should employ in vitro or animal models to further elucidate the role of PER2 in RA.
